Not applicableLooking for participantsNCT07652125What this trial is testingRGL-270 + ICI in Advanced NSCLCWho this might be right forNSCLC Guangdong Association of Clinical Trials 40
Large-scale testing (Phase 3)Ended earlyNCT03745222What this trial is testingTislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung CancerWho this might be right forCarcinoma, Non-Small-Cell Lung Celgene 1
Not applicableUnknownNCT04304638What this trial is testingReal-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLCWho this might be right forNon Small Cell Lung CancerStage III Non-small-cell Lung CancerEGFR Mutation-Related Tumors Chinese Academy of Medical Sciences 450
Early research (Phase 1)UnknownNCT05867303What this trial is testingA RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid TumorsWho this might be right forMelanomaUrothelial CarcinomaRenal Cell Carcinoma+3 more RemeGen Co., Ltd. 48
Early research (Phase 1)Looking for participantsNCT05098210What this trial is testingPersonalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerWho this might be right forAnatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more Fred Hutchinson Cancer Center 28
Testing effectiveness (Phase 2)Study completedNCT05386888What this trial is testingA Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLCWho this might be right forNSCLC, Stage III Genfleet Therapeutics (Shanghai) Inc. 65
Testing effectiveness (Phase 2)Study completedNCT02577341What this trial is testingNimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung CancerWho this might be right forNon-small-cell Lung Cancer Sun Yat-sen University 122
Large-scale testing (Phase 3)Study completedNCT00686959What this trial is testingChemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung CancerWho this might be right forNon Small Cell Lung Cancer Eli Lilly and Company 598
Large-scale testing (Phase 3)Study completedNCT03728556What this trial is testingCS1001 in Subjects With Stage III Non-Small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer Stage III CStone Pharmaceuticals 381
Not applicableNo Longer AvailableNCT04667234What this trial is testingExpanded Access of SotorasibWho this might be right forNon Small-cell Lung CancerLocally Advanced Unresectable NSCLCLocally Advanced Metastatic NSCLC Amgen
Not applicableStudy completedNCT00253708What this trial is testingMassage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic CancerWho this might be right forCancer Beth Israel Deaconess Medical Center 39
Large-scale testing (Phase 3)Study completedNCT04294810What this trial is testingTiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer Hoffmann-La Roche 620
Large-scale testing (Phase 3)Looking for participantsNCT07640789What this trial is testingA Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)Who this might be right forNon-small Cell Lung Cancer Stage III Sichuan Baili Pharmaceutical Co., Ltd. 418
Testing effectiveness (Phase 2)Looking for participantsNCT07742332What this trial is testingTargeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLCWho this might be right forEGFRNSCLC (Non-small Cell Lung Cancer)Locally Advanced Non-Small Cell Lung Cancer+2 more Peng Zhang 160
Testing effectiveness (Phase 2)Looking for participantsNCT06265285What this trial is testingComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramWho this might be right forAdvanced Esophageal Squamous Cell CarcinomaAdvanced Renal Cell CarcinomaClinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8+28 more Mayo Clinic 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT06448910What this trial is testingCadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLCWho this might be right forNSCLCLocally Advanced Lung Carcinoma Fudan University 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT06700421What this trial is testingPhase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation PneumonitisWho this might be right forUnresectable Locally Advanced Non-small Cell Lung Cancer Wei Zhou 32
Large-scale testing (Phase 3)Ended earlyNCT02322281What this trial is testingTIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet ChemotherapyWho this might be right forNon-small Cell Lung Cancer Clovis Oncology, Inc. 149
Large-scale testing (Phase 3)Looking for participantsNCT07361497What this trial is testingEvaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)Who this might be right forNon-small Cell Lung Cancer (NSCLC) Bristol-Myers Squibb 850
Early research (Phase 1)Study completedNCT02892123What this trial is testingTrial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing CancersWho this might be right forHER2-expressing Cancers Jazz Pharmaceuticals 279